About Brenus Pharma
Brenus Pharma is a company based in Issoire (France) founded in 2020. Brenus Pharma has raised $37.57 million across 2 funding rounds from investors including Crédit Agricole, Angelor and UI Investissement. Brenus Pharma offers products and services including STC 1010 and STC Platform. Brenus Pharma operates in a competitive market with competitors including IGM Biosciences, Imvax, Check-Cap, BriaCell Therapeutics and New Element Medicine, among others.
- Headquarter Issoire, France
- SectorsHealthcare
- Website brenus-pharma.com
- Social LinkedIn X
- Total Equity Funding$37.57M (USD)
in 2 rounds
- Latest Funding Round$12.57M (USD), Series A
Jul 2026
- InvestorsCrédit Agricole
& 7 more
Products & Services of Brenus Pharma
Brenus Pharma offers a comprehensive portfolio of products and services, including STC 1010 and STC Platform.
Immunotherapy targeting colorectal cancer to educate immune system against relapse.
Allogeneic system generating tumor antigen-focused treatments for solid tumors.
Funding Insights of Brenus Pharma
Brenus Pharma has successfully raised a total of $37.57M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.57 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.57M
- Total Rounds 2
- Last Round Series A — $12.57M
- First Round $25M
(Sep 2024)
- Investors Count 8
All 2 funding rounds of Brenus Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $12.57M | Series A | – | – | |
| Sep 2024 | $25M | Series A | – | Angelor |
8 investors in total: 8 institutional.
Investors in Brenus Pharma
Brenus Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Angelor and UI Investissement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
UI Investissement is engaged in private equity and investment services. | – | ui-investissement.com | Paris, France | |
Noshaq is recognized as a Liège-based investment fund providing financing solutions. | – | noshaq.be | Liege, Belgium | |
Investsud is engaged in supporting SMEs with sustainable investments. | – | investsud.be | Marche-en-Famenne, Belgium | |
- | – | sambrinvest.be | - | |
- | – | koreaomega.co.kr | - | |
Commercial banking services are provided across France by Credit Agricole. | 1988 | credit-agricole.fr | Paris, France | |
- | – | credit-agricole.com | - | |
Angelor is engaged in financing and supporting innovative entrepreneurs. | – | angelor.fr | Lyon, France |
Investor details for Brenus Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Brenus Pharma
11 people are tracked at Brenus Pharma (4 in leadership, 4 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Jacques Gardette | CEO | Leadership |
Aymeric Bordet | Chief Financial Officer | Leadership |
Paul Bravetti | CEO | Leadership |
Benoit Pinteur | Founder & Chief Scientific Officer | Leadership |
Pierre Morgon | Board Member | Board & advisors |
Laurence Comte Arassus | Board Member | Board & advisors |
Stéphane Loze | Board member | Board & advisors |
Hervé Gisserot | Board Member | Board & advisors |
Lionel Chalus | Lead Technical Operations | Team |
Lea Perles | Strategic Operations Lead | Team |
Iseulys Richert | R&d Scientist | Team |
Complete people profiles for Brenus Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Brenus Pharma
3 dated milestones of Brenus Pharma across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Brenus Pharma is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series A, of $12.6M.
Competitors of Brenus Pharma
Brenus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IGM Biosciences, Imvax, Check-Cap, BriaCell Therapeutics and New Element Medicine, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| igmbio.com | 2010 | Mountain View, United States | $102.67M | 181 | Antibodies for cancer and infectious disease treatments are developed. | |
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| check-cap.com | 2005 | Haifa, Israel | $9.88M | – | Developer of imaging capsules for colorectal cancer screening | |
| briacell.com | 2004 | Beverly Hills, United States | – | 16 | Developer of immunotherapies for the treatment of cancer | |
| atombp.com | 2012 | Zhenjiang, China | $152.05M | – | Drugs for cancer and metabolic diseases are developed. | |
| zymedi.com | 2019 | Incheon, South Korea | $29.54M | – | Therapeutics for multiple diseases are developed using Aminoacyl-tRNA Synthetase technology. | |
| promisdx.com | 2019 | Pasadena, United States | $10.8M | 9 | Non-invasive diagnostics for colorectal cancer screening are developed. | |
| cellgenesys.com | 1988 | Hayward, United States | $310,000 | – | Cell-based immunotherapies and oncolytic virus therapies for cancer are developed. | |
| photonpharmaceuticals.com | 2019 | Fort Collins, United States | $5.76M | – | Antigen presentation technology for personalized tumor immunotherapy is provided. |
Detailed competitors of Brenus Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Brenus Pharma
10 companies that operate in the same segment as Brenus Pharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Brenus Pharma
Brenus Pharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Brenus Pharma is headquartered in Issoire, France. It is registered at Issoire, Auvergne-rhone-alpes, France.
Jacques Gardette is the current CEO of Brenus Pharma.
Brenus Pharma is a funded company, having raised a total of $37.57M across 2 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Sep 2024.
Brenus Pharma was founded in 2020 in Issoire, France, where focus is placed on biotechnology for oncology. Immunotherapy solutions are developed, with STC-1010 targeted at metastatic colorectal cancer and other solid tumors. Operations center on advancing clinical-stage treatments within the pharmaceutical sector, supporting research and development for cancer therapies across Europe.
Brenus Pharma's top competitors include Imvax, IGM Biosciences and Check-Cap.
Brenus Pharma offers STC 1010 and STC Platform.
Brenus Pharma has 8 investors. Key investors include Crédit Agricole, Angelor, UI Investissement, Noshaq, and Investsud.